Drugs targeting human membrane proteins and novel stem cell protein reagents are designed by biocomputing tools and clinically evaluated for their therapeutic potential at "G2D" Center. G2D stands for "Genome to Drugs". New treatments against neurodegenerative diseases are pursued in collaboration with clinical research centers and hospitals.
